ACC Leadership Summit

A Panel Discussion Among Eight Interventional Cardiologists

March 2007

Study Description and Objectives

§    Review the COURAGE trial data studying outcomes of percutaneous coronary intervention (PCI) plus maximum medical therapy versus maximum medical therapy alone.

§    Discuss the SPIRIT-III trial examining Guidant’s XIENCE™ V Everolimus Eluting Coronary Stent System versus Boston Scientific’s TAXUS EXPRESS2™ Paclitaxel Eluting Coronary Stent System.

§    Evaluate the ABSORB trial regarding the Bioabsorbable Everolimus-Eluting Coronary Stent System.

§    Assess the OrbusNeich Genous Bio-engineered R Stent, which is coated with endothelial progenitor cells.

§    Review the Endeavor III trial comparing treatment with either the Abbott’s Endeavor zotarolimus-eluting stent or Cordis/Johnon &Johnson’s Cypher sirolimus-eluting stent.

§    Examine the issue of stent thrombosis in drug-eluting stents.

§    Discuss the ARMYDA-ACS trial about using atorvastatin (Pfizer’s Lipitor) as pre-treatment prior to PCI.

Companies and Products Mentioned in This Report

Inclusion Criteria

Hospitals Represented

§   Beth Israel Deaconess Medical Center, MA

§   Stanford University Medical Center, CA

§   University Hospital of Leicester, Leicester, UK

§   Columbia University Medical Center, NY

§   Duke University Medical Center, NC

§   Baylor College of Medicine, TX

§   Wythenshawe Hospital, Manchester, UK